Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of pazopanib and durvalumab for metastatic soft tissue sarcoma
KCT0003447Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pazopanib, durvalumab in soft tissue sarcoma (STS), sponsored by AstraZeneca. Started Apr 2019; status: completed.
02
Drugs
pazopanibdurvalumab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on KCT0003447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003447.